Different efficacy of osimertinib in pre-TKI treated NSCLC patients with brain metastases harboring EGFR exon 19del and L858R mutant.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21667
Abstract: e21667Background: Previous studies suggested that the efficacy of osimertinib was better in patients with epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) than exon 21 Leu858Arg (... read more here.
Keywords: egfr exon; osimertinib pre; different efficacy; efficacy osimertinib ... See more keywords